

Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study.

Mary-Ellen Taplin, Martin Gleave, Neal D. Shore, Angela Lopez-Gitlitz, Alexander Kretschmer, Eleni Efstathiou, Ronaldo Damião, Toshiyuki Kamoto, Ashley Ross, Alberto Briganti, Boris A. Hadaschik, Axel Heidenreich, Álvaro Juárez Soto, Oliver Brendan Rooney, Shaozhou Ken Tian, Lisa Wetherhold, Branko Miladinovic, Sharon McCarthy, Christopher P. Evans, Adam S. Kibel; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA; University of British Columbia, Vancouver, BC, Canada; START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC; Johnson & Johnson, Los Angeles, CA; Johnson & Johnson, Spring House, PA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil; University of Miyazaki, Miyazaki City, Japan; Northwestern University, Chicago, IL; Unit of Urology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy; University of Duisburg-Essen and German Cancer Consortium (DKTK) - University Hospital Essen, Essen, Germany; University Hospital of Cologne, Cologne, Germany; Hospital Universitario de Jerez de la Frontera, Cadiz, Spain; Johnson & Johnson, High Wycombe, United Kingdom; Johnson & Johnson, San Diego, CA; Johnson & Johnson, Bridgewater, NJ; University of Nevada, Reno, NV; Brigham and Women's Hospital, Boston, MA

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2026, issue of the *Journal of Clinical Oncology*.

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.

Mark A. Dickson, Karla V. Ballman, Mia C. Weiss, Steven Attia, Michael J. Wagner, Seth M. Pollack, Edwin Choy, Andrew J. Wagner, Breelyn A. Wilky, Lara E. Davis, Richard F. Riedel, Andrew Koff, William D. Tap; Memorial Sloan Kettering Cancer Center, New York, NY; Mayo Clinic Rochester, Rochester, MN; Division of Medical Oncology, Washington University, St. Louis, MO; Mayo Clinic Florida, Jacksonville, FL; Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Division of Hematology and Oncology, Northwestern University, Chicago, IL; Massachusetts General Hospital, Boston, MA; University of Colorado School of Medicine, Aurora, CO; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Duke Cancer Institute, Durham, NC

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2026, issue of the *Journal of Clinical Oncology*.

Event-free survival with adjuvant selpercatinib in stage IB-III A *RET* fusion-positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.

Jonathan W. Goldman, Xuening Yang, Maximilian Hochmair, Lin Wu, Hye Ryun Kim, Luis G. Paz-Ares, Damian Tobias Rieke, Melissa Lynne Johnson, James Chih Hsin Yang, Masahiro Tsuboi, Benjamin Besse, Nivedita Sharma, Patricia H. Maeda, Patrick Peterson, Bente Frimodt-Moller, Yi Yang, Alexander E. Drlon, Yi-Long Wu; University of California Los Angeles, Los Angeles, CA; Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria; Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria; The Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea; Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain; Charité University of Medicine Berlin, Berlin, Germany; Sarah Cannon Research Institute, Nashville, TN; Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University, Taipei City, Taiwan; Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Gustave Roussy, Villejuif and Paris-Sud University, Villejuif, France; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Cedar Knolls, NJ; Eil Lilly and Company, Indianapolis, IN; Eil Lilly and Company, Copenhagen, Denmark; Department of Thoracic Surgery, The Third People's Hospital of Chengdu; Affiliated Hospital of Southwest Jiaotong University; College of Medicine, Southwest Jiaotong University, Chengdu, Sichuan, China; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY; Lung Cancer Research Institute Department of Pulmonary Medicine II, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2026, issue of the *Journal of Clinical Oncology*.

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.

Chen Zhiwei, Fang Yang, Yongzhong Luo, Longhua Sun, Lin Wu, Zhengxiang Han, Yun Fan, Yanqiu Zhao, XingYa Li, Haipeng Xu, Xiangjiao Meng, Ying Liu, Zhiye Zhang, Hui Luo, Qin Shi, Xuelei Ma, Xuezhen Ma, Zhongmin Zhang, Michelle Y. Xia, Shun Lu; Shanghai Chest Hospital, Shanghai, Jiao Tong University, School of Medicine, Shanghai, Shanghai, China; Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China; Hunan Cancer Hospital, Changsha, Hunan, China; The First Affiliated Hospital of Nanchang University, Nanchang, China; The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China; Zhejiang Cancer Hospital, Hangzhou, China; Henan Cancer Hospital, Zhengzhou, China; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Fujian Provincial Tumor Hospital, Fuzhou, Fujian, China; Shandong Cancer Hospital and Institute, Jinan, China; Jilin Cancer Hospital, Changchun, Jilin, China; Oncology Department, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China; Jiangxi Cancer Hospital, Nanchang, Jiangxi, China; Fuzhou Pulmonary Hospital of Fujian, Fuzhou, Fujian, China; West China Hospital of Sichuan University, Chengdu, Sichuan, China; Qingdao Central Hospital, Qingdao, Shandong, China; Linyi People's Hospital, Linyi, China; Akeso Biopharma, Inc., Zhongshan, China; Shanghai Chest Hospital, Shanghai, Jiao Tong University, School of Medicine, Shanghai, China

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2026, issue of the *Journal of Clinical Oncology*.

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.

Brian M. Wolpin, Zev A. Wainberg, Andrew Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam Abbas Manji, Paul Eliezer Oberstein, Ignacio Garrido-Laguna, Christoph Springfield, Nilofer Saba Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Eileen M. O'Reilly; Dana-Farber Cancer Institute, Gastrointestinal Cancer Center, Boston, MA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; Department of Oncology, Mayo Clinic Florida, Jacksonville, FL; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; The University of Texas MD Anderson Cancer Center, Houston, TX; Paris-Saclay University, Digestive and Medical Oncology Department, Paul Brousse Hospital, APHP, Villejuif, France; Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY; NYU Langone Health, New York, NY; University of Utah Huntsman Cancer Institute, Salt Lake City, UT; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan; Revolution Medicines, Inc., Redwood City, CA; Revolution Medicines, Redwood City, CA; Memorial Sloan Kettering Cancer Center, New York City, NY

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2026, issue of the *Journal of Clinical Oncology*.